<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn id="d33e1224">
  <p id="ntpara0010">
   <sup>19</sup> Strategic Information, Global Hepatitis Programme, World Health Organization
  </p>
 </fn>
 <fn id="d33e1229">
  <p id="ntpara0015">Author Contribution</p>
 </fn>
 <fn id="d33e1232">
  <p id="ntpara0020">JH and MH conceived the manuscript. JH and AP wrote the manuscript. All other authors provided interviews to inform the Framework content, intellectual input, draft revision and editing and approved the final manuscript.</p>
 </fn>
 <fn id="d33e1235">
  <p id="ntpara0025">Data availability: N/A</p>
 </fn>
 <fn id="d33e1238">
  <p id="ntpara0030">Conflict of interest declaration</p>
 </fn>
 <fn id="d33e1241">
  <p id="ntpara0035">JH has received investigator-initiated funding and speaker fees from Gilead Sciences. AHS reports grants to her institution from ViiV Healthcare. ETH is the former director of the Medicines Patent Pool. NS has received investigator-initiated research funding from Gilead Sciences. AP has received investigator-initiated research funding from Gilead Sciences, MSD and AbbVie, and honoraria from Gilead Sciences. JVL reports grants and personal fees from AbbVie, Gilead Sciences and MSD, personal fees from CEPHEID and Janssen, all outside the submitted work. MS is principal investigator in an investigator-initiated trial sponsored by Gilead Sciences (received no PI fees, trial closed April 17th 2019) and reports an educational grant to travel to EASL 2019 (Gilead Sciences). SJH received honoraria from Gilead, unrelated to submitted work. AJT is advisory board member for Gilead Sciences, Arbutus Biopharma, AbbVie, BMS, Bayer, Roche, Ipsen, Eisai, Immunocore Ltd, Clear B Therapeutics, ViR therapeutics and has received speaker fees and investigator-initiated funding from Gilead Sciences, AbbVie and BMS. MHâ€™s Institute receives investigator initiated research funding from Gilead Sciences, Abbvie and BMS. JH received the Gilead Sciences Australia fellowship (2017). DW, CK, RA, RBL, MB, LA, AG, SH, RH, WL, RBM, SO, RP, MS, CWS, MT, ESS have nothing to declare.</p>
 </fn>
 <fn id="d33e1244">
  <p id="ntpara0040">Statement of financial support</p>
 </fn>
 <fn id="d33e1247">
  <p id="ntpara0045">The Burnet Institute received funding from the Qatar Foundation as part of their support for the World Innovations Summit for Health, 2018.</p>
 </fn>
</fn-group>
